文献速递临床免疫分子诊断

SNIBE Maglumi化学发光免疫分析法检测唾液SARS-CoV-2抗原的分析与临床评价

Analytical and clinical evaluations of SNIBE Maglumi chemiluminescent immunoassay for the detection of SARS-CoV-2 antigen in salivary samples.
PubMed 文献 · Clin Chem Lab Med · 2023-10-04

本研究评估了SNIBE Maglumi全自动化学发光免疫分析法(MAG-CLIA)在唾液样本中检测SARS-CoV-2抗原的分析性能与临床表现。分析性能包括检出限(LOD)为3 ng/L、重复性7.5%、线性良好;在228例医护人员唾液样本中,以3.5 ng/L为最佳截断值,敏感性和特异性分别为57.1%和97.0%,与分子检测的一致性为88.1%(Cohen's kappa 0.606)。结论认为分析性能满意,但唾液样本的临床性能不及鼻咽拭子。

要点

  • MAG-CLIA检测唾液SARS-CoV-2抗原的LOD为3 ng/L,重复性7.5%。
  • 以3.5 ng/L为截断值,敏感性57.1%、特异性97.0%。
  • 与RT-PCR一致性88.1%(kappa 0.606),唾液临床性能不及鼻咽拭子。

核心结论

  • MAG-CLIA分析性能满意,包括低于LOD的样本;唾液样本特异性高,但临床性能不及鼻咽拭子。

研究设计与样本

  • 在帕多瓦大学医院医护人员监测项目的 leftover 唾液样本中评估MAG-CLIA的临床表现,共228例。
  • 分析性能评估包括LOD、线性和精密度,并针对接近或低于声明LOD的值进行测试。
  • 唾液样本先经Lumipulse G SARS-CoV-2 Ag检测,值超过0.41 ng/L时进一步用TaqPath COVID-19 RT-PCR检测。

主要发现

  • MAG-CLIA的LOD为3 ng/L,重复性为7.5%。
  • 稀释两个样本(52.7 ng/L和211.4 ng/L)显示良好线性。
  • 228例样本中59例(25.9%)阳性,169例(74.1%)阴性。
  • 阳性样本MAG-CLIA SARS-CoV-2 sAg中位数(IQR)为5.03 ng/L(<0.001-35.8 ng/L),阴性样本为<0.001 ng/L(<0.001 ng/L)。
  • MAG-CLIA的AUC为0.795(95% CI: 0.720-0.871)。

关键数值与推荐

  • 最佳截断值3.5 ng/L时,敏感性57.1%(95% CI: 42.2-71.2%),特异性97.0%(95% CI: 93.2-99.0%)。
  • 与分子检测的一致性为88.1%(Cohen's kappa 0.606 [SE=0.066, p<0.001])。

临床怎么用

  • MAG-CLIA可用于唾液SARS-CoV-2抗原检测,但敏感性较低,阴性结果需分子检测确认。
  • 高特异性支持阳性结果作为快速筛查依据,但临床性能不及鼻咽拭子。

局限性

  • 临床性能评估仅基于医护人员唾液样本,未在更广泛人群中验证。
  • 唾液样本的临床性能不及鼻咽拭子,可能影响其单独用于诊断的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In this study, we describe the analytical and clinical performances of the SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay (MAG-CLIA) on salivary samples. METHODS: Limit of detection (LOD), linearity and precision were tested for values close to or below the declared LOD. Clinical performance of MAG-CLIA was evaluated on leftover salivary samples from the healthcare workers (HCW) surveillance program, at the University-Hospital of Padova. Salivary samples were analyzed by Lumipulse G SARS-CoV-2 Ag, and in case where the values exceeded 0.41 ng/L, further testing was conducted using TaqPathTM COVID-19 RT-PCR (Applied Biosystems, Thermo Fisher Scientific). RESULTS: The estimated MAG-CLIA LOD was 3 ng/L, with repeatability of 7.5 %. Good linearity was demonstrated by diluting two samples at 52.7 ng/L and 211.4 ng/L. Of the 228 HCW samples, 59/228 (25.9 %) were positive, 169/228 (74.1 %) were negative. MAG-CLIA SARS-CoV-2 sAg median level (and interquartile range [IQR]) was 5.03 ng/L (<0.001-35.8 ng/L) for positive and <0.001 ng/L (<0.001 ng/L) for negative samples. MAG-CLIA AUC was 0.795 (95 % CI: 0.720-0.871). Using the best cut-off, 3.5 ng/L, sensitivity and specificity were 57.1 % (95 % CI: 42.2-71.2 %) and 97.0 % (95 % CI: 93.2-99.0 %), respectively. The agreement with the molecular assay was 88.1 % (Cohen's kappa 0.606 [SE=0.066, p<0.001]). CONCLUSIONS: The analytical performances of MAG-CLIA are satisfactory, also when values below LOD were tested. In saliva samples, although specificity was elevated, clinical performance was not comparable with that on nasopharyngeal swabs (NPS).

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Padoan A, Talli I, Cosma C, et al. Analytical and clinical evaluations of SNIBE Maglumi chemiluminescent immunoassay for the detection of SARS-CoV-2 antigen in salivary samples. Clin Chem Lab Med. 2023. PMID: 37787733. doi:10.1515/cclm-2023-0947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。